Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab in Potentially Resectable Stage III NSCLC
NCT06424899Phase 2Recruiting
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in non-small cell lung cancer (NSCLC). Started May 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06424899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424899.